Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study
- PMID: 11104620
- DOI: 10.1006/gyno.2000.5984
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study
Abstract
Objectives: The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients.
Methods: Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles.
Results: In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD).
Conclusions: CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested.
Copyright 2000 Academic Press.
Similar articles
-
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2001 Jun;81(3):433-5. doi: 10.1006/gyno.2001.6182. Gynecol Oncol. 2001. PMID: 11371134 Clinical Trial.
-
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2002 Jan;84(1):32-5. doi: 10.1006/gyno.2001.6441. Gynecol Oncol. 2002. PMID: 11748972 Clinical Trial.
-
A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2006 Mar;100(3):586-90. doi: 10.1016/j.ygyno.2005.09.032. Epub 2005 Oct 24. Gynecol Oncol. 2006. PMID: 16249022 Clinical Trial.
-
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Cancer Treat Rev. 2016. PMID: 26559739 Review.
-
Carboplatin in refractory epithelial ovarian cancer.Semin Oncol. 1989 Apr;16(2 Suppl 5):45-8. Semin Oncol. 1989. PMID: 2655098 Review. No abstract available.
Cited by
-
Ovarian cancer: emerging molecular-targeted therapies.Biologics. 2012;6:147-54. doi: 10.2147/BTT.S24155. Epub 2012 Jun 20. Biologics. 2012. PMID: 22807625 Free PMC article.
-
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.Future Oncol. 2011 Dec;7(12):1415-28. doi: 10.2217/fon.11.124. Future Oncol. 2011. PMID: 22112317 Free PMC article. Review.
-
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332726 Free PMC article. Clinical Trial.
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
-
Management strategies for recurrent platinum-resistant ovarian cancer.Drugs. 2011 Jul 30;71(11):1397-412. doi: 10.2165/11591720-000000000-00000. Drugs. 2011. PMID: 21812505 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
